Brief: Regent Pacific Says Advised That Clinical Trial Approval Obtained Post Review Of SenstendTM
09/02/2021 09:48
Feb 9 (Reuters) - Regent Pacific Group Ltd 0575.HK :
* ADVISED THAT CLINICAL TRIAL APPROVAL WAS OBTAINED POST
FORMAL
REVIEW OF SENSTENDTM
* COMMENCEMENT OF RANDOMISED CLINICAL TRIAL DUE TO COMMENCE
IN
APRIL / MAY 2021
Source text for Eikon: ID:nHKS5zdTRZ
Further company coverage: 0575.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regent Pacific
See all newsBrief: Regent Pacific Says SenstendTM Approved By NMPA For Premature Ejaculation In China
Brief: Regent Pacific Says Deep Longevity To Launch U.S. Expansion In Q1 2026
Brief: Regent Pacific Shall Allot And Issue 63.4 Million Shares At Hk$0.485 Per Share
Brief: Regent Pacific Announces Submission Of Senstend New Drug Application To NMPA In China
Brief: Regent Pacific Enters Manufacturing And Supply Agreement For SENSTEND